SCHEMBL17467362

SCHEMBL17467362

c1ccc(-c2ccc3c(c2)-c2cccc(-c4nc(-c5ccccc5)nc(-c5ccccc5)n4)c2C3)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.39
ADORA1 P30542 2/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
MAPT P10636 3/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
TYRO3 Q06418 1/20 0.38
NTRK2 Q16620 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
ADORA2B P29275 1/20 0.38
TDP2 O95551 6/20 0.37
LMNA P02545 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GLA P06280 1/20 0.37
KDR P35968 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17467364 1.00 ADORA2A (0.39) ADORA2AADORA1MEN1KMT2AMAPT
SCHEMBL17467361 0.99 ADORA2A (0.38) ADORA2AADORA1MEN1KMT2AMAPT
SCHEMBL17467370 0.94 ADORA2A (0.39) ADORA2AADORA1MEN1KMT2AMAPT
SCHEMBL17467371 0.92 ADORA2A (0.38) ADORA2AADORA1MEN1KMT2AMAPT
SCHEMBL17467369 0.92 ADORA2A (0.38) ADORA2AADORA1MEN1KMT2AMAPT
SCHEMBL25720786 0.92 TDP2 (0.41) ADORA2AADORA1MEN1KMT2AMAPT
SCHEMBL17467372 0.92 ADORA2A (0.38) ADORA2AADORA1MEN1KMT2AMAPT
SCHEMBL17467389 0.90 ADORA2A (0.41) ADORA2AADORA1MEN1KMT2AMAPT
SCHEMBL17467365 0.90 ADORA2A (0.38) ADORA2AADORA1MEN1KMT2AMAPT
SCHEMBL17467391 0.90 ADORA2A (0.41) ADORA2AADORA1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11818949-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-11-14 US disclosed
US-11641774-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-05-02 US disclosed
US-20230130110-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-04-27 US disclosed
US-20230126221-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-04-27 US disclosed
US-20170054087-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2017-02-23 US disclosed
US-20170025618-A1 Organic Electroluminescent Materials and Devices UNIVERSAL DISPLAY CORPORATION 2017-01-26 US disclosed
US-20160093808-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2016-03-31 US disclosed
US-20160028021-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2016-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160028021-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD2, OCIAD1, OR10J3 ADORA2A 4607/4885ADORA1 4447/4885MEN1 1828/4885
US-20230130110-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES SOD1, PIEZO1, L1CAM ADORA2A 4012/4885ADORA1 4079/4885MEN1 452/4885
US-11818949-B2 Organic electroluminescent materials and devices EML4, TBCB, TERF2IP ADORA2A 3792/4885ADORA1 4162/4885MEN1 3089/4885
US-20170025618-A1 Organic Electroluminescent Materials and Devices TBCB, EML4, INMT ADORA2A 3210/4885ADORA1 4015/4885MEN1 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.